Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients

Background: The role of specific immunotherapy ( SIT) in elderly allergic patients is still debated. Objective: The aim of this study was to assess whether SIT is associated with a better control of symptoms and a better quality of life also in older allergic patients. Methods: The effect of injection SIT was assessed in 39 patients [ age 154 years, median 59; 29 patients (74%) with asthma, otherwise healthy] monosensitized to birch ( n = 20) and ragweed ( n = 19). Thirty-three younger subjects [ age < 50 years, median 35; 26 patients (79%) with asthma, otherwise healthy] monosensitized to birch ( n = 10) and ragweed ( n = 23), and 37 subjects >54 years old (25 males/12 females; age 55 - 79 years, median 59 years) monosensitized to birch ( n = 18) and ragweed ( n = 19) who refused to undergo SIT were enrolled as positive and negative controls, respectively. All groups had a disease duration < 10 years; the disease was inadequately controlled with standard drug therapies in all cases. SIT was carried out using the same extracts and was administered using a perennial schedule both in patients and controls. Seasonal therapies were the same in all groups and were not changed after SIT was started. After 1 - 5 years of SIT, patients and controls were asked to quantify symptom reduction on a visual analogue scale: reductions >50% were considered significant. Moreover, the use of cetirizine and/or salbutamol as an adjunct to standard therapies during the last pollen season was assessed as an objective measure of SIT outcome. Results: 37/39 (95%) patients versus 32/33 (97%) controls submitted to SIT reported a symptom reduction >50% after 1 - 5 years of SIT ( nonsignificant). The median clinical efficacy of SIT was 80% in both groups ( nonsignificant). 27/37 controls not submitted to SIT did not report any change in symptom severity at the follow-up visits, whereas 10/37 reported a more severe disease ( 4 subjects reported the appearance of seasonal asthma) (p < 0.001 vs. patients submitted to SIT). Patients used less frequently cetirizine (p < 0.001) and/or salbutamol ( p < 0.05) than controls not submitted to SIT. Conclusion: Injection SIT can be considered an effective therapeutic option in otherwise healthy elderly patients with a short disease duration whose symptoms cannot be adequately controlled by drug therapies alone. Copyright (C) 2004 S. Karger AG, Basel.